Friends of NFTBC
A perennial topic with REGN is the question of whether they will ever consummate a big deal - will they, won’t they? For all his apparent disapproval of pharma M&A in general, CEO Len Schleifer has also been pretty clear that he’s not against it entirely - it’s just that the price has to be right and there has to be some kind of highly compelling strategic angle. With this post I raise the possibility that such a candidate could now be in sight.
But I also stress that the post is speculative, and I would assign only an outside chance of some version of its contents coming to pass (let’s say 10-20%). Nevertheless, I do believe there is a fairly strong logical foundation to it as well as a tantalising window of opportunity where the stars have all momentarily aligned. It’s probably now or never. And so, in the full knowledge that this outcome might be unlikely, it’s kind of intriguing to think it through and write about it anyway. If nothing else, hopefully we’ll learn something useful along the way.
Regrettably, there isn’t much of a free preview on this one (such as I typically like to provide) because I intend to come to the point quite quickly and that would give the game away too soon. That said, once you’re in, there’s plenty of fare to chew on: regarding background, strategic rationale, the uniqueness of the situation at hand and even a deal model you can download and play with if you want to. If you would like to read the post for free you have three options: 1) use your one free post voucher (if you haven’t used it yet) 2) use your week-long free trial or 3) successfully refer a friend:
Or better still, I’d be delighted to welcome you into the elite tier of full NFTBC subscribers.
Thanks for reading NFTBC.
